Autobio Diagnostics (603658) Q2 2025 earnings summary

Executive summary

• Revenue for H1 2025 was ¥2.06 billion, down 6.65% year-over-year; net profit attributable to shareholders was ¥571 million, down 7.83% year-over-year.

• R&D investment reached ¥350 million, accounting for 16.99% of revenue, with 88 new product registrations and 661 CE certifications.

• The company continued to expand its global presence, with products in over 100 countries and new subsidiaries in Hong Kong, Hungary, and Indonesia.

Financial highlights

• Operating income: ¥2.06 billion, down 6.65% year-over-year.

• Net profit attributable to shareholders: ¥571 million, down 7.83% year-over-year.

• Operating cash flow: ¥410 million, down 17.22% year-over-year.

• Basic and diluted EPS: ¥1.02, down 6.42% year-over-year.

• Gross margin and net margin declined slightly; R&D expenses decreased due to capitalization.

Outlook and guidance

• The company expects continued growth opportunities in the IVD sector, driven by aging demographics, policy support, and technological innovation.

• Faces ongoing pricing pressure from centralized procurement and increased competition, but aims to leverage its broad product portfolio and innovation to maintain market share.